Ramez Naam

From Wikipedia, the free encyclopedia

Ramez Naam is a professional technologist and science fiction writer. He was involved in the development of widely used software products such as Microsoft Internet Explorer and Microsoft Outlook. His last role at Microsoft was as a Partner Group Program Manager in Search Relevance for Live Search.

He was the CEO of Apex Nanotechnologies, a company involved in developing nanotechnology research software before returning to Microsoft.[1]

Naam currently holds a seat on the advisory board of the Acceleration Studies Foundation, is a member of the World Future Society, a Senior Associate of the Foresight Institute, and a fellow of the Institute for Ethics and Emerging Technologies.[2][3]

He is the author of More Than Human: Embracing the promise of biological enhancement, which reviews new technologies and makes a case for embracing human enhancement, showing readers how new technologies are powerful new tools in humanity’s quest to improve ourselves, our offspring and our world.

Naam is also the recipient of the 2005 HG Wells Award for Contributions to Transhumanism, awarded by the World Transhumanist Association.[4]

Naam began publishing science fiction in 2012, with Nexus, from Angry Robot Books. It centers around an experimental nano-drug by that name. The sequel was Crux.[5]

In 2013, Naam published The Infinite Resource: The Power of Ideas on a Finite Planet.

He holds almost 20 patents in areas of email, web browsing, search, and artificial intelligence.

Bibliography

  • More than human: Embracing the promise of biological enhancement
  • Nexus: Mankind gets an upgrade
  • The infinite resource: The power of ideas on a finite planet
  • Crux: Upgrade in progress

References

  1. ↑ Ramez Naam at CrunchBase
  2. ↑ Ramez Naam
  3. ↑ Ramez Naam - biography, plus book reviews & excerpts
  4. ↑ Ramez Naam wins 2005 HG Wells Award for Contributions to Transhumanism
  5. ↑ Ramez Naam - Crux synopsis reveal

External links


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.